Neurourology and Urodynamics · 2013 · 96 citations · 12 references
MedicinePharmacologyPharmacotherapyBladder ManagementClinical PharmacologyVoiding DysfunctionBladder DysfunctionBladder Function AssessmentOveractive BladderOveractive Bladder ManagementUrinary IncontinenceBladder Overactivity TreatmentFemale Overactive BladderOveractive Bladder SymptomsPharmacologic Bladder ManagementPharmacological TherapyPlacebo Effect In TreatmentUrinary Urgency Incontinence
AIMS: To evaluate the potential of mirabegron, a selective β3-adrenoceptor agonist, for treatment of overactive bladder (OAB) symptoms. METHODS: A multicenter, randomized, double-blind, double-dummy, parallel group, placebo and active-controlled, Phase 2, proof-of-concept study was conducted. Eligible patients (n = 314) were enrolled into a single-blind, 2-week placebo run-in period followed by a randomized, double-blind, placebo-controlled treatment period. Patients received mirabegron 100 or 150 mg twice-daily (BID), placebo or tolterodine 4 mg extended release (ER) once-daily for 4 weeks. Primary endpoint was change from baseline to end-of-treatment in mean number of micturition episodes per 24 hr. Secondary endpoints included changes in mean volume voided per micturition; mean number of urinary incontinence, urgency urinary incontinence, and urgency episodes per 24 hr; severity of urgency; nocturia, and quality of life measures. Safety parameters included adverse events, laboratory tests, electrocardiogram parameters and post-void residual volume. RESULTS: Mirabegron 100 and 150 mg BID resulted in a statistically significant improvement versus placebo in mean change from baseline to end-of-treatment in the primary endpoint of micturition frequency (2.2 micturitions/24 hr vs. 1.2 micturitions/24 hr for both doses, adjusted P ≤ 0.01 for both comparisons). Mirabegron had a statistically significant effect versus placebo for most secondary endpoints, including quality of life variables. Despite a small increase in pulse rate, mirabegron demonstrated good safety and tolerability. CONCLUSIONS: Mirabegron was efficacious and well tolerated in patients with OAB symptoms and heralds the first of a new class of oral pharmacological therapy for OAB for more than 30 years.
12
Patient‐reported reasons for discontinuing overactive bladder medication
Joshua S. Benner, Michael B. Nichol, Eric S. Rovner et al. · British Journal of Urology · 2009 · 394 citations · Full text
Christopher R. Chapple, Tomasz Rechberger, P. J. MEFFAN et al. · British Journal of Urology · 2004 · 371 citations
Medicine, Pharmacology, Urology +15